Another clinical trial uses pan-HDACi panobinostat, combined with glucocorticoids, as primary treatment for acute GVHD demonstrates an enhanced H3 acetylation in both CD4+ and CD8+ T cells (161). The gene discussed is CD4; the disease is acute graft versus host disease.